Virtual ACC 2020 | PRONOMOS: Rivaroxaban Superior to Enoxaparin in Orthopedic Surgery

According to this new study presented virtually at the suspended American College of Cardiology (ACC) 2020 Scientific Session and published simultaneously in the New England Journal of Medicine (NEJM), rivaroxaban is more effective than enoxaparin in preventing venous thromboembolism during a period of immobilization after nonmajor orthopedic surgery of a lower limb.

Pronomos: Rivaroxaban

After an orthopedic surgery, there is a transitory period of reduced mobility during which the risk of deep vein thrombosis must be prevented; so far, enoxaparin was the best option for this. The efficacy of that drug is undisputed, but its uncomfortable administration, particularly for patients on bedrest at their homes, made us continuously seek for an option that was at least noninferior.

This international double-blind, parallel-group, noninferiority study randomized patients undergoing nonmajor orthopedic surgery of a lower limb to rivaroxaban or enoxaparin.

The efficacy endpoint was a composite of symptomatic distal or proximal deep vein thrombosis, pulmonary embolism or thrombosis-related death during the treatment period, or asymptomatic deep vein thrombosis. Researchers planned to test for superiority if rivaroxaban turned out to be noninferior.


Read also: Virtual ACC 2020 | PRECOMBAT: 10 Years for Surgery vs. Angioplasty in Left Main Coronary Artery Disease.


The safety endpoint included major bleeding (fatal, critical, clinically evident bleeding, or surgical bleeding requiring a reintervention) and nonmajor clinically relevant bleeding.

The study enrolled 3604 patients; the primary endpoint rate was 0.2% for rivaroxaban vs. 1.1% for enoxaparin (p < 0.001 for noninferiority and p = 0.01 for superiority).

The rates for major bleeding were practically identical: 1.1% vs. 1%, respectively.


Read also: Virtual ACC 2020 | TWILIGHT-DM: Ticagrelor Monotherapy in Diabetic Patients.


This study represents a new landmark in the history of prevention against deep vein thrombosis, with a drug that is both much more comfortable for patients as regards the route of administration and more effective, without compromising its safety.

Loading...

Original Title: Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.

Reference: C. Marc Samama et al. New England Journal of Medicine 2020, online before print y presentado simultáneamente en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Treatment of Atrial Functional Mitral Regurgitation

Atrial functional mitral regurgitation (aFMR), which results from atrial dilation without significant left ventricular dysfunction, accounts for approximately one-third of mitral regurgitation (MR) cases...

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...